Update on the success of the pneumococcal conjugate vaccine

Paediatrics and Child Health

Volumn 16, Issue 4, 2011, Pages 233-236

  Kellner, J D ^b   Bortolussi, Robert ^a   Finlay, Jane ^b   McDonald, Jane C ^b   Onyett, Heather ^c   Robinson, Joan L ^b   Rousseau Harsany, Élisabeth ^d  

^a IWK HEALTH CENTRE   (Canada)

^b Queen's University ^*

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Conjugate vaccine; Infant; Meningitis; Pneumococcal disease; Streptococcus pneumoniae; Vaccination

Indexed keywords

PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBODY BLOOD LEVEL; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; EMPYEMA; HOSPITALIZATION; HUMAN; IMMUNITY; INCIDENCE; INFECTION RISK; LOBAR PNEUMONIA; MICROBIAL COLONIZATION; MORBIDITY; MORTALITY; MYRINGOTOMY; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEROTYPE; SEROTYPE 19A; STREPTOCOCCUS PNEUMONIAE; TREND STUDY; VACCINATION; VACCINE PRODUCTION;

EID: 80053960706     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/16.4.233     Document Type: Review

References (33)

1. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: Update from the Calgary-Area Streptococcus pneumoniae Research (CASPER) study. Clin Infect Dis 2009;49:205-12.
2. Kellner JD, Scheifele D, Vanderkooi OG, Macdonald J, Church DL, Tyrrell GJ. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J 2008;27:526-32.
3. De Wals P, Robin E, Fortin E, Thibeault R, Ouakki M, Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2008;27:963-8.
4. Bjornson G, Scheifele DW, Bettinger J, et al. Effectiveness of pneumococcal conjugate vaccine in Greater Vancouver, Canada: 2004-2005. Pediatr Infect Dis J 2007;26:540-2.
5. Paulus S, David ST, Tang W, et al. Incidence of invasive pneumococcal disease after introduction of the Universal Infant Immunization Program, British Columbia (2002-2005). Can Commun Dis Rep 2006;32:157-61.
6. Lefebvre B, Bourgault AM. Programme de Surveillance du Pneumocoque, Rapport 2009. Institut national de santé publique du Québec. 〈http://www.inspq.qc.ca/publications/notice.asp?E=p&NumPublication= 1180〉 (Accessed on March 30, 2011).
7. Bruce MG, Deeks SL, Zulz T, et al. International Circumpolar Surveillance System for Invasive Pneumococcal Disease, 1999-2005. Emerg Infect Dis 2008;14:25-33.
8. Pilishvili T, Lexau C, Farley MM, et al; for the Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41.
9. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet 2007;369:1179-86. (Pubitemid 46527876)
10. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007;119:707-15. (Pubitemid 46556669)
11. Lipsitch M. Bacterial vaccines and serotype replacement: Lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999;5:336-45. (Pubitemid 29289447)
12. Beall B, McEllistrem MC, Gertz RE Jr, et al; Active Bacterial Core Surveillance Team. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006;44:999-1017.
13. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468-72. (Pubitemid 46847304)
14. Bettinger J, Scheifele DW, Kellner JD, et al; for Members of the Canadian Immunization Monitoring Program, ACTive (IMPACT). The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010;28:2130-6.
15. Bettinger JA, Scheifele DW, Kellner JD, et al. Emergence of Serotype 19A in Canadian Children: IMPACT 2000-2009. Oral Presentation at 9th Canadian Immunization Conference, Quebec City, December 2010. Can J Infect Dis Med Microbiol 2010;21:178.
16. Pelton SI. Replacement pneumococcal disease in perspective. Clin Infect Dis 2008;46:1353-5. (Pubitemid 351589932)
17. Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008;14:275-81.
18. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009;199:776-85.
19. Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: An increasing concern in Canada. Can Respir J 2008;15:85-9. (Pubitemid 351676396)
20. Goldbart AD, Leibovitz E, Porat N, et al. Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine. Scand J Infect Dis 2009;41:182-7.
21. Roxburgh CS, Youngson GG, Townend JA, Turner SW. Trends in pneumonia and empyema in Scottish children in the past 25 years. Arch Dis Child 2008;93:316-8. (Pubitemid 352025830)
22. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006;25:250-4. (Pubitemid 43379067)
23. Hendrickson DJ, Blumberg DA, Joad JP, Jhawar S, McDonald RJ. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2008;27:1030-2.
24. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: A matched case-control study. Lancet 2006;368:1495-502. (Pubitemid 44634693)
25. Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2010;29:546-9.
26. Desai S, McGeer A, Quach-Thanh, Elliott D. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Update on the Use of Conjugate Pneumococcal Vaccines in Childhood. Can Commun Dis Rep 2010;36(ACS 12):1-21.
27. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008;26:3277-81.
28. Roche PW, Krause V, Cook H, et al; Enhanced Invasive Pneumococcal Disease Surveillance Working Group; Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008;32:18-30.
29. Health Canada. Drugs and Health Products. Notice of Decision for SYNFLORIX™. 〈www.hcsc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1- decision/drugmed/nd-ad-2009-synflorix-119056-eng.php〉 (Accessed on March 30, 2011).
30. Health Canada. Drugs and Health Products. Notice of Decision for PREVNAR® 13. 〈www.hcsc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1- decision/drugmed/nd-ad-2010-prevnar-13-122881-eng.php〉 (Accessed on March 30, 2011).
31. McGeer A, Desai S. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Update on pediatric pneumococcal disease and recommended use of conjugate pneumococcal vaccines. Can Commun Dis Rep 2010;36(ACS-3):1-30.
32. O'Brien KL, Wolfson LJ, Watt JP, et al; for the Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 2009;374:893-902.
33. Advance Market Commitments for Vaccines. GAVI Alliance.〈www. vaccineamc.org/index.html〉 (Accessed on March 30, 2011).